SCHEMBL5035699

SCHEMBL5035699

O=C(O)[C@H]1CCCCN1C(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.64
L3MBTL1 Q9Y468 2/20 0.62
CA2 P00918 1/20 0.59
HPGD P15428 3/20 0.58
MAPK1 P28482 1/20 0.58
ALDH1A1 P00352 2/20 0.56
FASN P49327 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
MEN1 O00255 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
GAA P10253 1/20 0.53
GYS1 P13807 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
DGAT1 O75907 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035705 1.00 TDP1 (0.64) TDP1L3MBTL1CA2HPGDMAPK1
SCHEMBL5036076 0.95 CA2 (0.64) TDP1L3MBTL1CA2HPGDMAPK1
SCHEMBL1750558 0.95 CA2 (0.64) TDP1L3MBTL1CA2HPGDMAPK1
SCHEMBL3575904 0.91 TDP1 (0.66) TDP1L3MBTL1CA2HPGDALDH1A1
SCHEMBL3575901 0.91 TDP1 (0.66) TDP1L3MBTL1CA2HPGDALDH1A1
SCHEMBL5702058 0.89 HPGD (0.54) TDP1L3MBTL1CA2HPGDMAPK1
SCHEMBL5702038 0.89 HPGD (0.54) TDP1L3MBTL1CA2HPGDMAPK1
SCHEMBL13804291 0.89 HPGD (0.55) TDP1L3MBTL1HPGDMAPK1ALDH1A1
SCHEMBL13229 0.86 CA2 (0.67) TDP1L3MBTL1CA2ALDH1A1SMN1; SMN2
SCHEMBL28789388 0.86 CA2 (0.67) TDP1L3MBTL1CA2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1263730-B1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS SERONO LAB (CH) 2008-01-09 EP claimed
US-6770656-B2 NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2004-08-03 US claimed
US-20030216427-A1 Amine derivatives for the treatment of apoptosis MERCK SERONO SA (CH) 2003-11-20 US claimed
EP-1263730-B1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS SERONO LAB (CH) 2008-01-09 EP disclosed
US-6770656-B2 NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2004-08-03 US disclosed
US-20030216427-A1 Amine derivatives for the treatment of apoptosis MERCK SERONO SA (CH) 2003-11-20 US disclosed
EP-1263730-A1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS Applied Research Systems ARS Holding N.V. (AN) 2002-12-11 EP disclosed
WO-2001060798-A1 AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216427-A1 Amine derivatives for the treatment of apoptosis BAD, BAX, BCL2 TDP1 1038/4885L3MBTL1 2909/4885CA2 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.